This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Fovista

Ophthotech Corp.

Drug Names(s): E10030, OAP030A

Description: E10030 is an aptamer-based compound directed against PDGF-B. Pharmacology studiesindicate that E10030 binds to PDGF-B with high specificity and affinity and inhibits the functions of PDGF-B both in vitro and in vivo. In preclinical studies, E10030 demonstrated the potential to regress neovascularization when used in combination with a VEGF-A inhibitor. Inexperiments involving models of ocular vascularization, concurrent inhibition of PDGF-B and VEGF-A signaling was superior to inhibition of the VEGF-A pathway alone.

E10030 is a pegylated aptamer containing 32 monomeric units arranged as a linear sequence of three oligonucleotide segments connected by non-nucleotide hexaethylene glycol spacers. The aptamer terminates in a hexylamino linker to which two 20-kilodalton monomethoxy polyethylene glycol units are covalently attached via the two amino groups on a lysine residue.

Deal Structure: Archemix and Eyetech (OSI)
In April 2004, Archemix entered into a research and license agreement with Eyetech Pharmaceuticals for the discovery, development and commercialization of aptamers for ophthalmologic diseases and conditions. Eyetech was acquired by OSI Pharmaceuticals in November 2005 and subsequently renamed (OSI) Eyetech.

Eyetech (OSI) and Ophthotech
In 2007, OSI Pharmaceuticals announced that its subsidiary, (OSI) Eyetech has entered into an agreement with Ophthotech to divest its anti-platelet derived growth factor (PDGF) aptamer program. Under the terms of the agreement, OSI will transfer to Ophthotech all rights in the PDGF aptamer program, including rights to its pre-clinical compound E10030, in exchange for an up-front cash payment, an equityinterest in Ophthotech and potential future milestones and royalties. Financial terms ofthe agreement have not been disclosed.

NitroMed and Archemix
In November 2008, NitroMed and Archemix...See full deal structure in Biomedtracker

Partners: Astellas Pharma, Inc. Archemix Corp. Novo Nordisk A/S Nektar Therapeutics Novartis AG


Fovista News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug